

Monday 20 November 2023

08:30 – 18:00	Registration desk open		
	Room: Foyer		
09:00 – 11:00	WORKSHOP 1: Careers in Industry and Beyond	WORKSHOP 2: Using machine learning in clinical pharmacology workflows	
	Room: Cockle Bay Room 2	Room: Meeting Room C3.2	
	Chair: Dr Saba Naghipour, Griffith University, Kinjal Patel, UNSW Sydney, Jana Zielinski, The University of Melbourne, Mariah Stavrou, UNSW Sydney and Ilsa Wojt, The University of Sydney	Chair: A/Prof Matt Doogue, University of Otago, Christchurch and A/Prof Jonathan Brett, St Vincent's Hospital Sydney, UNSW Sydney	
	Careers in industry <i>Orin Chisholm, The University of Sydney</i> <i>Prajni Sadananda, Biogen</i> <i>Kumaran Mani, Astra Zeneca</i> <i>Paul Young, Ab Initio</i>	W101. Pharmacometrics and machine learning <i>Prof Pierre Marquet, University Hospital of Limoges</i>	
		W102. Machine learning, clinical pharmacology, and the quality use of medicines <i>Dr David Liew, Austin Health</i>	
11:00 – 11:15	Comfort break		
11:15 – 13:10	WORKSHOP 3: Advanced analytical approaches for drug discovery	WORKSHOP 4: Computational toxicology: Transforming toxicity testing in the 21st century	WORKSHOP 5: Challenges and opportunities in transforming clinical pharmacology: lessons from three continents
	Room: Cockle Bay Room 2	Room: Meeting Room C3.1	Room: Meeting Room C3.2
	Chair: Dr Alaa Abdul-Rhida, The Florey Institute of Neuroscience and Mental Health and Chantel Mastos, Monash University	Chair: Raymond Lui, Computational Pharmacology and Toxicology Laboratory, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney	Chair: Dr Jana Stojanova, St Vincent's Hospital Sydney and A/Prof Jane Carland, St Vincent's Hospital Sydney / UNSW Sydney
	W103. Curve fitting methods for quantifying the kinetics of G-protein-coupled receptor signalling <i>Dr Sam Hoare, Pharmeconomics Pharmacology Data Analysis and Consulting</i>	W106. Using computers in toxicology education: Python for PK calculations <i>Dr Slade Matthews, The University of Sydney</i>	W110. Innovations in immunosuppressant therapeutic drug monitoring implemented in France <i>Prof Pierre Marquet, University Hospital Limoges/University of Limoges</i>
	W104. Quantification of Allosteric and Biased Signalling <i>Dr Celine Valant, Monash University</i>	W107. Toxicological modelling and simulation at the molecular and cellular levels <i>Raymond Lui, The University of Sydney</i>	W111. Clinical application of alternative sampling technologies in Australia <i>Dr Richard Kevin, St Vincent's Hospital Sydney / UNSW Sydney</i>
	W105. Use of pharmacokinetic models and analysis in drug discovery <i>Dr Xiao (Derek) Zhu, School of Pharmacy, Fudan University</i>	W108. Intro to TK and PBTK methods in toxicology and risk assessment <i>Dr Antti Mikkonen, Environment Protection Authority Victoria</i>	W112. Clinical pharmacology across continents – perspectives from Chile <i>Dr Jana Stojanova, St Vincent's Hospital Sydney</i>
		W109. Artificial intelligence and machine learning for toxicity testing <i>Daniella James-New, The University of Sydney</i>	

13:10 – 13:40	STUDENT FORUM SIG AGM	TOXICOLOGY SIG AGM	CLINICAL PHARMACOLOGY SIG AGM
13:40 – 14:10	Lunch break (not included)		
14:10 – 16:10	WORKSHOP 6: Innovation and Industry in Pharmacology	WORKSHOP 7: Pharmacogenomics SIG: Updates on our understanding and implementation of pharmacogenomic knowledge	WORKSHOP 8: Generative AI and the future of pharmacology education
	Room: Cockle Bay Room 2	Room: Meeting Room C3.1	Room: Meeting Room C3.2
	Chair: Dr Elizabeth Johnstone, University of Western Australia and Prof Daniel Hoyer, The University of Melbourne	Chair: Dr Nuala Helsby, University of Auckland	Chair: A/Prof Tina Hinton, The University of Sydney, Prof Emilio Badoer, RMIT University, Dr Gregg Maynard, Charles Sturt University
	W113. Endo Axiom and Oral insulin: the gap between an academic paper and a clinical trial <i>Dr Nicholas Hunt, Endo Axiom</i>	W118. Pharmacogenetics and the Environment: A Bigger Picture of the Ethnic Factors that Influence Drug Disposition and Response <i>Dr Carwyn Davies, GSK Sydney</i>	W121. Investigating generative AI to build research and scholarship capacity in pharmacology and toxicology education <i>Dr Megan Anakin, The University of Otago</i>
	W114. Innovation at the interface of industry and academia <i>Dr Andrew Harvey, The University of Queensland</i>	W119. The Potential of Model Informed Precision Dosing and Pharmacogenomics for Clozapine Therapy <i>Sam Mostafa, Monash University</i>	W122. AI-Enhanced Health Education: Shaping health professionals for tackling future complex problems <i>A/Prof Kellie Charles, The Sydney University</i>
	W115. Next generation therapeutics inspired by psychedelics from nature <i>Josh Ismin, Psylo</i>	W120. Marching towards health system funding of preemptive pharmacogenomic testing which integrates with electronic medical record(EMR)systems across the Globe <i>A/Prof Leslie Sheffield, MyDNA Life Australia PTY LTD</i>	W123. Academic integrity and generative AI <i>Prof Adam Bridgeman, The University of Sydney</i>
	W116. The Dangerous Business of Stepping Out Your Door: D1 to First in Man in Pharma <i>A/Prof Laura Jacobson, The Florey Institute of Neuroscience and Mental Health</i>		W124. Quality of information and bias in generative AI <i>Prof Emilio Badoer, RMIT University</i>
	W117. Inosi Therapeutics: The role of serendipity in moving from academic to translational research <i>Dr Tracy Gaspari, Inoisi Therapeutics</i>		
16:10 – 16:40	INNOVATION & INDUSTRY SIG AGM	PHARMACOGENOMICS SIG AGM	EDUCATION FORUM AGM
17:00 – 18:00	Conference opening and keynote address		
	Room: Cockle Bay Room 2		
	Prof Kevin Pflieger, ASCEPT President A/Prof Nicola J Smith, ASCEPT SAC Chair Chair: Prof Kevin Pflieger, ASCEPT President		
	100. Challenging Dogma: Time to Change Practice with Some New Tricks <i>Dr Emily G. McDonald, Centre for Outcomes Research and Evaluation (CORE)</i>		
18:30 – 20:00	Welcome reception		Sponsored by  Bellberry Limited supporting research and ethics
	Room: Foyer		

07:30 – 18:00	Registration desk open			
	Room: Foyer			
08:30 – 09:30	British Pharmacological Society keynote address			
	Room: Cockle Bay Room 2			
	Chair: Prof Kevin Pflieger, ASCEPT President			
	200. GPCRomics: Oh, the Places You'll Go!			
	<i>Dr Fiona Murray, University of Aberdeen</i>			
09:30 – 10:25	Morning tea with exhibitors			
	Poster presentations: Clinical Pharmacology, Drug Discovery, Respiratory and Inflammation, Innovation and Industry, Toxicology			
	Room: Foyer			
10:30 – 12:30	Symposium 1: New frontiers for the translation of drug discovery into the patient	Symposium 2: Transforming our perception of how the RAAS contributes to fibrosis	Symposium 3: Transformations in toxicology	Symposium 4: Pharmacogenomics in Oceania
	Room: Cockle Bay Room 2	Room: Meeting Room C3.1	Room: Meeting Room C3.2	Room: Cockle Bay Room 1
	Chairs: Brendan Wilkins, UNSW Sydney and Dr Liz Johnstone, Harry Perkins Institute of Medical Research, University of Western Australia	Chairs: Prof Owen Woodman, Monash University and Dr Simone De Luca RMIT University	Chair: Dr Slade Matthews, The University of Sydney and <i>Dr Ganna Shayakhmetova, ISI Institute of Pharmacology and Toxicology of National Academy of Medical Sciences of Ukraine</i>	Chair: A/Prof Alison Shield, The University of Sydney and Sam Mostafa, Monash University
10:30 – 11:00	201. New therapeutics require new health economic modelling approaches <i>Prof Zanfina Ademi, Monash University</i>	205. Lessons from the lung – current and novel approaches from treating fibrosis <i>A/Prof Jane Bourke, Monash University</i>	209. Advances in toxicology inform health risk assessment - how ACTRA has contributed in Australia <i>Prof Brian Priestly, Monash University</i>	213. What can DNA tell us about the human settlement of the Pacific and why does it matter? <i>Prof Lisa Matisso-Smith, The University of Otago</i>
11:00 – 11:30	202. The journey beyond the bench <i>Dr Robert Shepherd, Dimerix Limited</i>	206. Inactivation of the local cardiac renin angiotensin system improves cardiac performance after myocardial infarction <i>Zunhan (Francis) Lu, University of Queensland</i>	210. Toxicokinetic solutions for dynamic environmental problems <i>Antti Mikkonen, Environmental Protection Agency</i>	214. Oncology Pharmacogenomics and Aboriginal Australians <i>Prof Andrew Somogyi, The University of Adelaide</i>
11:30 – 12:00	203. Application of organoids to accelerate drug discovery into the patient <i>Prof Michael Kassiou, The University of Sydney</i>	207. Targeting the AT2 receptor as an effective means of treating fibrosis <i>Dr Yan Wang, Monash University</i>	211. Use and Assessment of New Approach Methods by the Australian Pesticides and Veterinary Medicines Authority <i>Selma Kaasinen, Australian Pesticides and Veterinary Medicines Authority</i>	215. An update on pharmacogenetics relevant for New Zealand Māori and Pacific peoples & challenges for equitable access to “precision medicine” <i>Dr Nuala Helsby, The University of Auckland</i>
12:00 – 12:30	204. Discovering and translating drugs to treat coronary artery disease beyond standard modifiable risk factors <i>Prof Gemma Figtree, The University of Sydney</i>	208. An update on how the RAAS can be targeted to treat liver fibrosis <i>Dr Chandana Herath, Austin Health</i>	212. Strengths & weaknesses of PBPK modelling in a regulatory context <i>Michael Roberts, The University of Queensland</i>	Panel discussion <i>Prof Lisa Matisso-Smith, The University of Otago, Prof Andrew Somogyi, The University of Adelaide and Dr Nuala Helsby, The University of Auckland</i>
12:30 – 13:25	Lunch with exhibitors			
	Poster presentations: Clinical Pharmacology, Drug Discovery, Respiratory and Inflammation, Innovation and Industry, Toxicology			
	Room: Foyer			

Supported by



13:30 – 15:00	Oral presentations 1: Drug Discovery	Oral presentations 2: Drug Disposition and Response	Oral presentations 3: Respiratory and Inflammation	Oral presentations 4: Clinical Pharmacology
	Room: Cockle Bay room 2	Room: Meeting room C3.1	Room: Meeting room C3.2	Room: Cockle Bay room 1
	Chairs: Dr Angela Finch, UNSW and Ms Ting Fu, Monash University	Chairs: A/Prof Cornelia Landersdorfer and Alice Terrill, Monash University	Chairs: Dr Simone De Luca, RMIT University and Dr Chantal Donovan, The University of Technology Sydney	Chairs: A/Prof Jonathan Brett, St Vincent's Hospital and UNSW and Dr Jana Stojanova, St Vincent's Hospital
13:30 – 13:45	216. β 2-Adrenoceptor-Mediated Invasion in Triple Negative Breast Cancer is Driven by HOXC12 <i>Terrance Lam, Monash University</i>	222. Extracellular vesicles as a liquid biopsy to predict drug exposure and response <i>Dr Zivile Useckaite, Flinders University</i>	228. EP4, a novel mitochondrial uncoupler, reduces disease features in obesity-associated severe asthma <i>Dr Richard Kim, University of Technology Sydney</i>	234. I feel like I'm working at Amazon". Pharmacists' experience of outpatient telepharmacy <i>Dr Jane Carland, St Vincent's Hospital, UNSW Sydney</i>
13:45 – 14:00	217. Small molecule activation of glucose-6-phosphate dehydrogenase (G6PD) <i>Joshua Caley, UNSW</i>	223. Dichloroacetate decreases dihydropyrimidine dehydrogenase activity in cancer patients: application of mouse transcriptomics <i>Dr Anneke Blackburn, Australian National University</i>	229. Pulmonary and vascular consequences of influenza A virus infection in atherosclerotic mice <i>Madison Coward-Smith, RMIT University</i>	235. Infliximab or adalimumab antidrug-antibody complex size has more clinical value than concentration <i>Prof Murray Barclay, Christchurch Hospital</i>
14:00 – 14:15	218. Physicochemical graph neural network for learning protein-ligand interaction fingerprints from sequence data <i>Dr Anh TN Nguyen, Monash University</i>	224. Hepatic Protein Signatures of Chronic Polypharmacy, Monotherapy, and Deprescribing in Aged Mice <i>Kevin Winardi, University of Sydney</i>	230. Investigating the pathophysiological effects of geography-specific landscape fires smoke <i>Dr Henry Gomez, University of Newcastle/ Hunter Medical Research Institute</i>	236. Examining methods to assess busulfan exposure in paediatric stem cell transplant recipients <i>Maxwell Thompson, The University of Queensland</i>
14:15 – 14:30	219. Exploring Spexin-1 and Predicted Spliceforms: Insights into GPR161 and GAL2R Signalling <i>Kinjal Patel, UNSW Sydney</i>	225. Clozapine-Induced Cardiotoxicity: Investigating reactive species associated with metabolite cycling <i>Ellen Kingston, The University of Auckland</i>	231. Defining the cross-tissue communication between lungs and white adipose tissue in COPD <i>Wei Wang, RMIT University</i>	237. Pregnancy in patients receiving tacrolimus: blood and plasma concentrations and gestational outcomes <i>Prof Benedetta Sallustio, The Queen Elizabeth Hospital</i>
14:30 – 14:45	220. A novel single-cell fluorescence-microscopy based analysis for detection of biomarkers of cellular-senescence <i>Vijayraghavan Seshadri, University of Tasmania</i>	226. Preclinical behavioural recognition cages to detect health impacts of polypharmacy and deprescribing <i>Dr John Mach, The University of Sydney / NSLHD/ Kolling Institute</i>	232. PF670462 attenuates stiffness and strain induced fibrogenesis in precision cut lung slices <i>Dr Daniel Tan, University of Melbourne</i>	238. Can we predict saliva penetration of drugs?: a systematic review <i>Anh Thi Nguyen, The University of Sydney</i>
14:45 – 15:00	221. Characterisation of the pro-atherosclerotic orphan G protein-coupled receptor, GPR146 <i>Brendan Wilkins, UNSW Sydney</i>	227. CD38 catalyses nicotinamide mononucleotide (NMN) base exchange <i>Dr Romanthi Madawala, UNSW Sydney</i>	233. A 3D mesothelioma co-culture model to improve translational potential of immunotherapy treatments <i>Aimee Stenekes, University of Technology Sydney</i>	239. The clinical impact of urate self-monitoring to improve allopurinol persistence in gout <i>Toni Michael, School of Pharmacy, The University of Sydney</i>
15:00 – 15:55	Afternoon tea with exhibitors			
	Room: Foyer			
15:00 – 15:30	DRUG DISCOVERY SIG AGM	CARDIOVASCULAR SIG AGM	DRUG DISPOSITION & RESPONSE SIG AGM	GASTROINTESTINAL-UROGENITAL SIG AGM
	Room: Cockle Bay Room 2	Room: Meeting Room C3.1	Room: Meeting Room C3.2	Room: Cockle Bay Room 1

16:00 – 17:30	ASCEPT Garth McQueen Student Oral Prize	Oral presentations 5: Drug Discovery, Cardiovascular & Neuropharmacology	Oral presentations 6: Pharmacogenomics / Pharmacoepidemiology	Oral presentations 7: Clinical Pharmacology Trainee / Toxicology
	Room: Cockle Bay Room 2	Room: Meeting Room C3.1	Room: Meeting Room C3.2	Room: Cockle Bay Room 1
	Chair: A/Prof Kellie Charles, The University of Sydney	Chairs: Dr Christopher Draper-Joyce, Florey Institute of Neuroscience & Mental Health, Dr Luke Grundy, Flinders University and Tayla Gibson Hughes, La Trobe University	Chairs: Dr Kathryn Burns, The University of Auckland and Dr Edwin Tan, The University of Sydney	Chairs: Raymond Lui, The University of Sydney and Dr Nazila Jamshidi, The University of Sydney and Sydney Local Health District
16:00 – 16:15	240. Developing an optogenetic system to shine a light on intracellular GPCR signalling <i>Chantel Mastos, Monash University</i>	246. Targeting adenosine receptors for the treatment of myocardial infarction and heart failure <i>Dr Bui San Thai, Monash University</i>	252. Indications for pharmacogenomic testing in Australia <i>Dr Sophie Stocker, The University of Sydney</i>	258. PAGANZ Nick Holford Prize Awardee: Time course of biomarkers of inflammation following birth and surgery <i>Abigail Bokor, University of Auckland</i>
16:15 – 16:30	241. Inhibition of the AT4R/IRAP to reduce renal fibrosis in chronic kidney disease <i>Sharenya Chelvaretnam, Monash University</i>	247. Improving the therapeutic application of an anti-fibrotic peptide by conjugation to nanoparticles <i>Deidree Somanader, Monash University</i>	253. Factors associated with antipsychotic use in people with dementia in Australia <i>Edward Lau, The University of Sydney</i>	259. Association between frailty and polypharmacy or multimorbidity in hospitalised adults <i>Dr Joshua Inglis, Flinders Medical Centre, Flinders University and University of Adelaide</i>
16:30 – 16:45	242. Probing the molecular basis of P2X1 receptor activation and inactivation using cryo-EM <i>Felix Bennetts, Monash University</i>	248. Dissecting endothelin-dependent signalling to identify new targets for fibrosis-related cardiac dysfunction <i>Dr Simon Foster, QIMR Berghofer Medical Research Institute</i>	254. Trajectories of oral bisphosphonate use after hip fractures: a population-based cohort study <i>Miriam Tim Yin Leung, Monash University</i>	260. A prospective audit of incidence and management of aspiration events in patients with acute poisoning <i>Dr Rowena Penafiel, Royal Prince Alfred Hospital</i>
16:45 – 17:00	243. Neurogenic inflammation exacerbates urinary tract infection in mice <i>Harman Sharma, Flinders University</i>	249. Exploring A2B receptor regulated human cardiac fibroblast phosphoproteome for fibrosis target discovery <i>Joel Coffie, Monash University</i>	255. Association of the Drug Burden Index exposure with outcomes: a systematic review <i>Dr Bonnie Liu, University of Sydney</i>	261. High-fructose diet changes brain' tissue biochemical parameters and male rats' sexual behavior <i>Dr Ganna Shayakhmetova, 1SI Institute of Pharmacology and Toxicology of National Academy of Medical Sciences of Ukraine</i>
17:00 – 17:15	244. Exploring molecular determinants underpinning high potency of MIPS3215 at adenosine A2B receptor <i>Cam Sinh Lu, Monash University</i>	250. Single target-dual therapy at M4 muscarinic receptors for the treatment of schizophrenia <i>Dr Celine Valant, Monash Institute of Pharmaceutical Sciences</i>	256. Symptomatic and preventive medication use in people with Alzheimer's disease: 10-year study <i>Shin Liao, Monash University</i>	262. Acute toxicity of Thai PM 2.5 in zebrafish embryos <i>Pinnakarn Techapichetvanich, Mahidol University</i>
17:15 – 17:30	245. Antibiotic combinations against Pseudomonas aeruginosa strains with different resistance mechanisms <i>Alice Terrill, Monash University</i>	251. Exploring cell senescence in iAstrocytes and iMicroglia from ALS patients <i>Alexandra Maximova, The University of Sydney</i>	257. Real-world evidence of antipsychotic utilization in Australia (2000-2021) using two datasets <i>Ramya Padmavathy Radha Krishnan, The University of Sydney</i>	263. Predicting the arrhythmogenic risk of drugs from the hypothetical 'worst case' drug <i>Dr Stewart Heitmann, Victor Chang Cardiac Research Institute</i>
17:30 – 18:30	British Toxicological Society keynote address			
	Room: Cockle Bay Room 2			
	Chair: Prof Kevin Pflieger, ASCEPT President			
19:00 – 23:00	264. Identification of Novel Toxicophores that Target Mitochondrial Respiratory Chain Complexes to Inform Drug Safety <i>Prof Marion MacFarlane, University of Cambridge</i>			
	Student Dinner (registered attendees only) Venue: Fratelli Brothers			

08:00 – 17:00	Registration desk open			
	Room: Foyer			
08:30 – 09:00	Gillian Shenfield Early Educator Award			
	Room: Cockle Bay Room 2			
	Chair: A/Prof Tina Hinton, Chair, Education Forum			
	300. Assessment redevelopment to improve task authenticity and evaluation of critical analysis skills Dr Jennifer Irvine, Monash University			
09:00 – 09:30	Early Achievement Award for Women			
	Room: Cockle Bay Room 2			
	Chair: A/Prof Elly Djouma, Chair, Equity, Diversity & Inclusion Forum			
	301. Antidepressants for pain in older adults: preliminary results from a systematic review Dr Sujita Narayan, The University of Sydney			
09:30 – 10:25	Morning tea with exhibitors			
	Poster presentations: Cardiovascular, Drug Disposition and Response, Education, Neuropharmacology, Pharmacogenomics, Pharmacoepidemiology, Gastrointestinal-Urogenital			
	Room: Foyer			
10:30 – 12:30	Symposium 5: Preclinical and clinical aspects of psychedelics in complex mental health disorders	Symposium 6: Heart of innovation: exploring technologies for cardiovascular research	Symposium 7: Pharmacokinetic drug-drug interactions – from microsomes to patients	Symposium 8: Pharmacoepidemiology across the lifespan
	Room: Cockle Bay Room 2	Room: Meeting Room C3.1	Room: Meeting Room C3.2	Room: Cockle Bay Room 1
	Chairs: Prof Emeritus Daniel Hoyer, The University of Melbourne, and A/Prof Bridin Murnion, St Vincent's Hospital Sydney and UNSW Sydney	Chairs: Dr Anida Velagic and Dr Chengxue (Helen) Qin, Monash Institute of Pharmaceutical Sciences	Chairs: Dr Sophie Stocker, The University of Sydney and Joshua Inglis, Flinders Medical Centre	Chairs: Dr Edwin Tan and Dr Mouna Sawan, The University of Sydney
10:30 – 11:00	302. The development of non-hallucinogenic antidepressants inspired by psychedelic natural products William Jorgensen, Psylo Bio Sydney	306. Advancing therapeutic development for cardiovascular disease with a preclinical human model of heart tissue Dr Shiang (Max) Lim, St Vincent's Institute of Medical Research	310. DDIs arising from modulation of drug metabolising enzyme activities: Mechanisms and in vitro – in vivo extrapolation Prof John Miners, Flinders University	314. Paediatric pharmacoepidemiology: starting to come of age A/Prof Madlen Gazarian, UNSW Sydney
11:00 – 11:30	303. Low dose psychedelics: Promise or placebo? Vince Polito, School of Psychological Science	307. Amnion cell-based therapies in cardiovascular disease Prof Chris Sobey, La Trobe University	311. Application of PBPK modelling for the prediction of pharmacokinetic DDIs and clinical pharmacokinetic DDI study design Dr Thomas Polasek, Certara	315. Perinatal pharmacoepidemiology Dr Erin Keltly, The University of Western Australia
11:30 – 12:00	304. Psychedelic assisted psychotherapies for alcohol and other drugs A/Prof Jonathan Brett, St. Vincent's Hospital Sydney and UNSW Sydney	308. New viral technologies for manipulating cardiac cell function Dr Melissa Reichelt, The University of Queensland	312. Pharmacoepidemiology approaches for evaluating pharmacokinetic DDIs in populations Dr Juiana de Oliveira Costa, UNSW Sydney	316. Pharmacoepidemiology in adult populations: a focus on prescription opioids A/Prof Natasa Gisev, UNSW Sydney
12:00 – 12:30	305. Jungle medicines: ayahuasca inspired psychedelic drugs for clinical mental health and addiction treatment Dr Daniel Perkins, The University of Melbourne and Psycae Institute	309. The role of extracellular vesicles in cardiometabolic disease Nimna Perera, Monash Institute of Pharmaceutical Sciences	313. Clinical decision support in prescribing systems to mitigate risks from pharmacokinetic DDIs A/Prof Matthew Doogue, Christchurch Hospital and The University of Otago, Christchurch	317. Pharmacoepidemiology with older adults: opportunities and challenges Ilsa Wojt, The University of Sydney
12:30 – 13:25	Lunch with exhibitors			
	Poster presentations: Cardiovascular, Drug Disposition and Response, Education, Neuropharmacology, Pharmacogenomics, Toxicology, Gastrointestinal-Urogenital			Supported by PROTO  AXIOM
	Room: Foyer			

13:30 – 15:30	Bellberry New Investigator Award	Sponsored by  Bellberry Limited supporting research and ethics
	Room: Cockle Bay Room 2	
	Chair: A/Prof Bridin Murnion, St Vincent’s Hospital Sydney and UNSW Sydney	
13:30 – 14:00	318. A LASEREDD Focus: Lentiviral-Driven Directed Evolution of Optimised G Protein-Coupled Receptors for Biologics Discovery <i>Dr Christopher Draper-Joyce, The Florey Institute of Neuroscience and Mental Health</i>	
14:00 – 14:30	319. Developing a new pre-clinical model of metabolic syndrome for testing pharmacotherapies and beyond <i>Dr Maria Jelinic, La Trobe University</i>	
14:30 – 15:00	320. Ensuring sustainability in healthcare through partnering with stakeholders to guide safe and effective medicine use <i>Dr Mouna Sawan, The University of Sydney</i>	
15:00 – 15:30	321. Cystic fibrosis transmembrane conductance regulator modulators Elexacaftor/Tezacaftor/Ivacaftor during pregnancy <i>Dr Elena K. Schneider-Futschik, The University of Melbourne</i>	
15:30 – 15:55	Afternoon tea with exhibitors	
	Room: Foyer	
16:00 – 17:00	Rand Medal	
	Room: Cockle Bay Room 2	
	Chair: Prof Kevin Pflieger, ASCEPT President	
	322. From Serotonin to Neuropeptides and back: Translational Research in Pharma and Academia <i>Prof Emeritus Daniel Hoyer</i>	
17:00 – 18:00	ASCEPT AGM	
	Room: Cockle Bay Room 2	
19:00 – 23:00	Meeting dinner	Sponsored by  Biodesign Australia
	Venue: Dockside Darling Harbour (registered attendees only)	

ASCEPT, APFP & APSA Joint Congress

1 – 4 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | [#ascept-apfp-apsa](https://twitter.com/ascept-apfp-apsa)

Supported by:







23rd International Congress of Therapeutic Drug Monitoring & Clinical Toxicology



Singapore 2025

5–8 October
Grand Copthorne Waterfront Hotel
www.iatdmct2025.org

20th World Congress of Basic and Clinical Pharmacology 2026

[#WCP2026 | wcp2026.org](https://wcp2026.org)



WCP 2026

12–17 July 2026 Melbourne/Narrm, Australia




Thursday 23 November 2023

08:00 – 15:45	Registration desk open			
	Room: Foyer			
09:00 – 10:00	Japanese Pharmacological Society keynote address			
	Room: Cockle Bay room 2			
	Chair: Prof Kevin Pflieger, ASCEPT President			
	400. Neuroimmune mechanisms of stress: Insights from a mouse model <i>Prof Tomoyuki Furuyashiki, Kobe University</i>			
10:00 – 10:25	Morning tea with exhibitors			
	Room: Foyer			
	NEUROPHARMACOLOGY SIG AGM	RESPIRATORY & INFLAMMATION SIG AGM	PHARMACOEPIDEMIOLOGY SIG AGM	
	Room: Cockle Bay Room 2	Room: Meeting Room C3.1	Room: Meeting Room C3.2	
10:30 – 12:30	Symposium 9: Defying time: Understanding and Preventing Age-Related Diseases	Symposium 10: Unravelling Organ Crosstalk in Cardiorespiratory and Neurological Diseases	Symposium 11: Educating prescribers of the future	Symposium 12: The impact of clinical pharmacology across drug development
	Room: Cockle Bay Room 2	Room: Meeting Room C3.1	Room: Meeting Room C3.2	Room: Cockle Bay Room 1
	Chair: Dr Melissa Reichelt, The University of Queensland and Prof Christopher Sobey, La Trobe University	Chairs: Dr Chantal Donovan, The University of Technology Sydney and Prof Ross Vlahos, RMIT University	Chairs: A/Prof Barb Kemp-Harper, Monash University and Dr Darren Roberts, Royal Prince Alfred Hospital	Chairs: Frances Stringer, GSK
10:30 – 11:00	401. Attenuation of the PI 3-kinase signalling pathway leads to increases in lifespan and health span <i>Prof Peter Shepherd, University of Auckland</i>	405. Can the immune system be targeted to treat hypertension and end organ damage? <i>Prof Grant Drummond, La Trobe University</i>	409. Performance of Prescribing Skills Assessment ANZ in final year medical students – student experience and skills performance <i>Prof Sarah Hilmer, The University of Sydney</i>	413. Model informed drug development (MIDD) to accelerate Phase 3 start <i>Chiara Zecchin, GSK</i>
11:00 – 11:30	402. Ovarian metabolism as a target to support women's health with age <i>Dr Lindsay Wu, UNSW Sydney</i>	406. Air Pollution-induced respiratory complications: what about the heart? <i>Prof Doan Ngo, The University of Newcastle</i>	410. Preparation for prescribing and Prescribing Skills Assessment in NZ - pre-intern level prescribing, requirements for basic physician training, and beyond <i>Dr Paul Chin, The University of Otago</i>	414. Ethnopharmacology past, present and future perspectives <i>Romina Nand, GSK</i>
11:30 – 12:00	403. Cardiac adiposity in aging; a potential target for treatment of cardiac arrhythmias? <i>Dr James Bell, La Trobe University</i>	407. The liver-lung axis contributes to secondary bacterial pneumonia <i>Prof Steven Bozinovski, RMIT University</i>	411. Preparation for prescribing and Prescribing Skills Assessment at The University of Sydney - programmatic approach to skill development, creating simulations for workplace assessments of prescribing, and student feedback about preparation needs <i>A/Prof Kellie Charles, The University of Sydney</i>	415. Impact of Clinical Pharmacology in Paediatric Drug Development <i>Shaun Kumar, Parexel</i>
12:00 – 12:30	404. Hypertension and ageing – a challenging pharmacological landscape <i>A/Prof Tracey Gaspari, Monash University</i>	408. They are not born equal <i>Prof Hui Chen, The University of Technology Sydney</i>	412. The National Prescribing Curriculum post National Prescribing Service- Where to next? <i>Dr Ivan Bindoff, Senior Research Fellow, University of Tasmania</i>	416. Leveraging Model-Informed Drug Development (MIDD) in Oncology: A Case Study with Relugolix <i>Yu-Wei Wayne Lin, Certara</i>
12:30 – 13:25	Lunch with exhibitors and ASCEPT student poster finalists presentation			
	Room: Foyer			

13:00 – 13:25	EDI workshop			
	Room: Cockle Bay Room 2			
	Chairs: A/Prof Elly Djouma, Chair EDI Forum, & Brendan Wilkins, Chair-elect, EDI Forum			
	Panel: ECR member: Nilushi Karunaratne Student Forum member: Emma Zhang Committee members: Suong Ngo, Sheila Doggrell, Rima Caccetta, Betty Exintaris, Tina Hinton			
13:30 – 15:00	Oral presentations 8: Innovation and Industry / Urogenital and Gastrointestinal	Oral presentations 9: Cardiovascular Sponsored by  	Oral presentations 10: Education	Oral presentations 11: Clinical Pharmacology
	Room: Cockle Bay Room 2	Room: Meeting Room C3.1	Room: Meeting Room C3.2	Room: Cockle Bay Room 1
	Chairs: Dr Iris Lim, Bond University and Dr Sab Ventura, Monash University	Chairs: Zunhan (Francis) Lu, The University of Queensland and A/Prof Anthony Vinh, La Trobe University	Chairs: Dr Jennifer Irvine, Monash University and Dr Slade Matthews, The University of Sydney	Chairs: Dr Nicholas Farinola, Central Adelaide Local Health Network and A/Prof Bridin Murnion, St Vincent's Hospital Sydney and UNSW Sydney
13:30 – 13:45	417. Human duodenum uptake and animal model toxicity of oral insulin nanotechnology (EA-1) <i>Dr Nicholas Hunt, University of Sydney</i>	423. Testosterone and the transgender heart, insight from a transgender male mouse model <i>Kai Robertson, Griffith University</i>	429. Innovative educational program to enhance pharmacy student knowledge and confidence in pharmacogenomics <i>Ruby Soueid, The University of Sydney</i>	435. The effect of compulsory indications in electronic hospital prescriptions on prescriber behaviour <i>Lorna Pairman, University of Otago</i>
13:45 – 14:00	418. Assessing alpha-1 antagonist prazosin cytotoxicity on bladder cancer cells and bladder function <i>Liam O'Callaghan, Bond University</i>	424. Sex matters—impact of HFD and low-dose SGLT2i on rodent cardiometabolic phenotype <i>Abhipree Sharma, Monash University</i>	430. Insights from student justifications for the choice of responses to multiple-choice questions <i>Dr Anna-Marie Babey, University of New England</i>	436. Evaluating deprescribing recommendations at scale in discharge summaries using natural language processing <i>Dr Kenji Fujita, Kolling Institute, University of Sydney</i>
14:00 – 14:15	419. A novel mouse model of bladder mucosal denervation <i>Dr Luke Grundy, Flinders University</i>	425. Lipoxin A4 improves cardiac remodelling and function in diabetes-associated cardiac dysfunction <i>Ting Fu, Monash University</i>	431. Can students identify mistakes when watching videos? <i>Dr Marina Junqueira Santiago, Macquarie University</i>	437. Evaluation of Partnered Pharmacist Medication Charting at Southern Adelaide Local Health Network <i>Vasilios Sotiropoulos, SA Pharmacy</i>
14:15 – 14:30	420. The Functional Role of Phosphodiesterase Isoenzymes in the Isolated Porcine Urethra <i>Eriq Burovski, Bond University</i>	426. Characterising vascular endothelial cell heterogeneity during angiotensin II-induced hypertension <i>Tayla Gibson Hughes, La Trobe University</i>	432. Impact of technology-enhanced learning strategies on student psychological motivation and performance <i>A/Prof Tina Hinton, The University of Sydney</i>	438. People with dementia and carers' medication management information needs: A scoping review <i>Alexander Clough, University of Sydney</i>
14:30 – 14:45	421. Effects of cranberry and D-mannose in a porcine UPEC-induced bladder infection <i>Jenane Konesan, UNSW</i>	427. Targeting the AT4 receptor/IRAP reverses type 2 diabetes-induced cardiovascular dysfunction and remodelling <i>Cameron Hollands, Monash University</i>	433. Using clinical case studies to build professional skills: A case study <i>Dr Suong N T Ngo, The University of Adelaide</i>	439. Dosing errors with paracetamol in Australians aged 12 and over, 2017-2023 <i>Annabelle Chidiac, The University of Sydney</i>

14:45 – 15:00	422. Comparison of diabetes-induced bladder dysfunction in vitro and in vivo <i>Aidan Mckee, Bond University</i>	428. Contrasting the pro-oxidant/pro-inflammatory profile of diabetic rat myocardium with human endothelial cells <i>Dr Anida Velagic, Monash Institute of Pharmaceutical Sciences (MIPS)</i>	434. Implementation of a professional practice unit to prepare for industry-based work-integrated learning <i>A/Prof Trisha Jenkins, RMIT University</i>	440. Efficacy and Safety of Opioids for Osteoarthritis: Systematic Review and Meta-Analysis <i>Dr Christina Abdel Shaheed, University of Sydney</i>
15:00 – 15:15	Afternoon tea break Room: Foyer			
15:20 – 15:50	Awards and meeting close Room: Cockle Bay Room 2 Chair: A/Prof Bridin Murnion, ASCEPT President Elect			



MONASH INSTITUTE OF PHARMACEUTICAL SCIENCES
Better Medicines by Design
monash.edu/mips



WORLD-CLASS PHARMACY AND PHARMACEUTICAL SCIENCE RESEARCH

Monash Institute of Pharmaceutical Sciences (MIPS) is a dynamic, innovative and ambitious centre of research and learning, with a growing emphasis on cutting edge global projects. More than 450 MIPS scientists research drug discovery, design, delivery and use. Our therapeutic strengths lie in neuroscience and mental health, cardiovascular and metabolic health, and global health.

Find out more monash.edu/mips

#1 In Asia Pacific for Pharmacy and Pharmacology (QS 2016-2022)

Top 3 globally for Pharmacy and Pharmacology (QS 2017-2022)

\$40M+ external research income

400+ publications per year


220 PhD candidates

282 staff

Download meeting app



Annual Scientific Meeting



View speakers, program and event information.

How to download:

- Download the Event App by EventsAIR from iTunes / Google Play
- Enter event code: **ascept2023**
- Log in using your ASCEPT 2023 registration email and PIN



Android



Apple



Web

<https://expertevents.eventsair.com/attendeeapp/ascept-2023/ascept2023>

CELEBRATING 20 YEARS OF EXCELLENCE



Bellberry Limited
supporting research and ethics

Australia's largest reviewer



Human Research Ethics Committees

Working across all phases of clinical and device trials, and social and behavioural studies, our teams support researchers in private, public, academic and government settings Australia-wide.

Since 2004 we have supported more than...

1 of CTN
3 clinical
trials in
Australia

1,300+ research
organisations

6,000+ investigators
and site staff

10,000+ research
applications



Participant
Centred

We care...

With two key objectives:
• to protect the welfare
of human research
participants, and improve
the quality, efficiency and
effectiveness of research.

Learn more >



Not-For-Profit
&
Philanthropic

We give...

We support grants for
people, projects and
direct action initiatives.

Learn more >



Certified &
Internationally
Accredited

We lead...

We are NHMRC certified,
and AAHRPP accredited
for excellence and ethically
sound processes. The first
and only organisation to
achieve this in Australia.

Learn more >



Clinical Trial
Activity Report
(CTAR) 2022

We know...

Our 2022 Clinical Trial
Activity Report shows
the continued strength
of Australia in FIH and
Phase 1 trials.

Full report available >



For more information about Bellberry and our services >

www.bellberry.com.au

+61 8 8361 3222

bellberry@bellberry.com.au

